CLL | Tumor

Marialice’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021, 9:30pm

Video

Treating CLL with CALQUENCE® (acalabrutinib)

Friday Frontline: First Patient to Receive CAR-T Cell Therapy Dies, Cancer Organizations Appeal to President for COVID-19 Vaccine Priority Access, and More

February 19th 2021, 4:00pm

Article

From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.

Jim’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021, 1:00pm

Video

Treating CLL with CALQUENCE® (acalabrutinib)

Adding to the Regimen: NCCN Updates in Leukemia and Lymphoma

February 15th 2021, 4:00pm

Article

The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

January 18th 2021, 4:00pm

Video

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.

Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment

January 15th 2021, 10:00pm

Video

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.

Adding Copiktra to Standard of Care Chemotherapy Combination in CLL Could Improve Outcomes, But Not Without Toxicities

January 14th 2021, 3:00pm

Video

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.

The Treatment Journey of a Patient with CLL

December 31st 2020, 4:00pm

Podcast

In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with chronic lymphocytic leukemia, about his diagnosis and treatment journey.

Early Use of Fixed-Duration Venclexta-Rituxan Combo in Patients with Relapsed/Refractory CLL Effective, And Does Not Compromise Subsequent Therapy Response in Patients Who Need Retreatment

December 14th 2020, 4:00pm

Article

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Venclexta Added to Novel Combination Therapy Elicits High Responses in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

December 14th 2020, 2:00pm

Article

Among 27 patients with relapsed/refractory chronic lymphocytic leukemia patients who completed all 12 cycles of the triplet therapy, 100% of patients had a complete or partial response to the treatment—with 41% achieving a complete response.